SILO (SILO Pharma) Growth Rank : 0 (As of Apr. 03, 2025)

View and export this data going back to 2012. Start your Free Trial

What is SILO Pharma Growth Rank?

SILO Pharma has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

SILO Pharma Growth Rank Related Terms

Thank you for viewing the detailed overview of SILO Pharma's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

SILO Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SILO Pharma Inc (NAS:SILO) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

677 N. Washington Boulevard, Sarasota, FL, USA, 34236

Website

https://www.silopharma.com

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

Executives

Eric Weisblum	director, officer: President and CCO	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Daniel E. Ryweck	officer: Chief Financial Officer	712 VISTA BLVD #305, WACONIA MN 55387
Jeff Pavell	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Kevin Munoz	director	560 SYLVAN AVE, SUITE 3160, ENGLEWOOD CLIFF NJ 07632
Wayne Linsley	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Adam C Wasserman	officer: Chief Financial Officer	1643 ROYAL GROVE WAY, WESTON FL 33327
Leonard M Schiller	director
Joel Alan Stone,	director	1772 SABAL PALM DR., BOCA RATON FL 33432
Parker Walter Van Eps	director	C/O PROSPECT ENERGY CORPORATION, 10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Richard Brand	director, officer: Chairman and CEO	10 E. 40TH STREET, 44TH FLOOR, NEW YORK NY 10016
Whalehaven Capital Fund Ltd	10 percent owner	P O BOX HM 1027, HAMILTON D0 HMDX
Vadim Mats	officer: VP of Business Development	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Donald Ptalis	director, officer: CFO	72 POND ROAD, WOODBURY NY 11797
Melvin Schlossberg	director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY	72 POND ROAD, WOODBURY NY 11797